EP0463157A4 - Lfa-3 as a vaccine adjuvant - Google Patents

Lfa-3 as a vaccine adjuvant

Info

Publication number
EP0463157A4
EP0463157A4 EP19910904441 EP91904441A EP0463157A4 EP 0463157 A4 EP0463157 A4 EP 0463157A4 EP 19910904441 EP19910904441 EP 19910904441 EP 91904441 A EP91904441 A EP 91904441A EP 0463157 A4 EP0463157 A4 EP 0463157A4
Authority
EP
European Patent Office
Prior art keywords
lfa
vaccine adjuvant
vaccine
adjuvant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19910904441
Other versions
EP0463157A1 (en
Inventor
Barbara P. Wallner
David W. Thomas
Mary A. V. Crimmins
Christopher D. Benjamin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen Inc
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc filed Critical Biogen Inc
Publication of EP0463157A1 publication Critical patent/EP0463157A1/en
Publication of EP0463157A4 publication Critical patent/EP0463157A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70528—CD58
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP19910904441 1990-01-24 1991-01-24 Lfa-3 as a vaccine adjuvant Withdrawn EP0463157A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46914090A 1990-01-24 1990-01-24
US469140 1990-01-24

Publications (2)

Publication Number Publication Date
EP0463157A1 EP0463157A1 (en) 1992-01-02
EP0463157A4 true EP0463157A4 (en) 1992-06-03

Family

ID=23862575

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19910904441 Withdrawn EP0463157A4 (en) 1990-01-24 1991-01-24 Lfa-3 as a vaccine adjuvant

Country Status (5)

Country Link
EP (1) EP0463157A4 (en)
JP (1) JPH04506666A (en)
AU (1) AU7300091A (en)
CA (1) CA2049931A1 (en)
WO (1) WO1991011194A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223394A (en) * 1989-04-10 1993-06-29 Biogen, Inc. Recombinant dna molecule comprising lymphocyte function-associated antigen 3 phosphatidylinositol linkage signal sequence
WO1993006852A2 (en) * 1991-10-07 1993-04-15 Biogen, Inc. Methods of improving allograft or xenograft tolerance by administration of an lfa-3 or cd2 binding protein
US6764681B2 (en) 1991-10-07 2004-07-20 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
US5795572A (en) * 1993-05-25 1998-08-18 Bristol-Myers Squibb Company Monoclonal antibodies and FV specific for CD2 antigen
WO1995024217A1 (en) * 1994-03-08 1995-09-14 Dana-Farber Cancer Institute Methods for modulating t cell unresponsiveness
ATE513913T1 (en) 2000-05-10 2011-07-15 Sanofi Pasteur Ltd IMMUNOGENIC POLYPEPTIDES ENCODED BY MAGE MINIGENE AND USES THEREOF
US7858095B2 (en) 2001-07-24 2010-12-28 Astellas Us Llc Method for treating or preventing sclerotic disorders using CD-2 binding agents
AU2003223527B2 (en) 2002-04-09 2009-01-15 Sanofi Pasteur Limited Modified CEA nucleic acid and expression vectors
CN101124327A (en) 2003-10-08 2008-02-13 圣诺菲·帕斯图尔公司 Modified CEA/B7 vector
WO2005115436A1 (en) * 2004-05-07 2005-12-08 Astellas Us Llc Soluble lfa-3 polypeptide for treating viral disorders
CN101835488B (en) 2007-09-04 2018-10-26 美国政府(由卫生和人类服务部、疾病控制和预防中心的部长所代表) The heat inactivation of rotavirus
WO2014025198A2 (en) * 2012-08-09 2014-02-13 주식회사 한독 Lfa3 mutant, fusion protein in which target-specific polypeptides are connected to the mutant or lfa3 cd2 binding region, and use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989010938A1 (en) * 1988-05-04 1989-11-16 Dana-Farber Cancer Institute Protein micelles
WO1989012458A1 (en) * 1988-06-14 1989-12-28 Cell Med, Inc. Heterofunctional cellular immunological reagents, vaccines containing same and methods for the use of same

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4956281A (en) * 1987-06-03 1990-09-11 Biogen, Inc. DNA sequences, recombinant DNA molecules and processes for producing lymphocyte function associated antigen-3

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989010938A1 (en) * 1988-05-04 1989-11-16 Dana-Farber Cancer Institute Protein micelles
WO1989012458A1 (en) * 1988-06-14 1989-12-28 Cell Med, Inc. Heterofunctional cellular immunological reagents, vaccines containing same and methods for the use of same

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, vol. 108, no. 11, 14th March 1988, page 502, abstract no. 92752w, Columbus, Ohio, US; G. TIEFENTHALER et al.: "Purified lymphocyte function-associated antigen-3 and T11 target structure are active in CD2-mediated T cell stimulation" & EUR. J. IMMUNOl. 1987, 17(12), 1847-50 *
See also references of WO9111194A1 *

Also Published As

Publication number Publication date
WO1991011194A1 (en) 1991-08-08
JPH04506666A (en) 1992-11-19
EP0463157A1 (en) 1992-01-02
AU7300091A (en) 1991-08-21
CA2049931A1 (en) 1991-07-25

Similar Documents

Publication Publication Date Title
US5182109C1 (en) Vaccine preparation comprising a bacterial toxin adjuvant
GB9001766D0 (en) Vaccines
AP9200368A0 (en) Vaccine
IL106280A0 (en) Use of gm-csf as a vaccine adjuvant
EP0391997A4 (en) Vaccine
AP9100332A0 (en) Vaccines
EP0463157A4 (en) Lfa-3 as a vaccine adjuvant
GB8918206D0 (en) Tuberculosis vaccine
AU8537091A (en) Membrane-derived antiflea vaccines
OA09636A (en) Vaccine
GR3022679T3 (en) Vaccine adjuvant comprising a tetra-polyol
ZA924670B (en) Ccv vaccine
GB9020584D0 (en) Vaccine
GB9021004D0 (en) Acellular vaccines
EP0453452A4 (en) Vaccine
IL94510A0 (en) Influenza vaccine
GB9011358D0 (en) Vaccines
GB9006097D0 (en) Vaccines
GB9214435D0 (en) Vaccine carrier or adjuvant
IE900354L (en) Vaccine composition
ZA909516B (en) Novel vaccine
GB8922651D0 (en) Vaccine
GB9124390D0 (en) Vaccines
GB9110067D0 (en) Vaccines
GB9119167D0 (en) Vaccines

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19911012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB IT LI LU NL SE

A4 Supplementary search report drawn up and despatched

Effective date: 19920421

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB IT LI LU NL SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Withdrawal date: 19921230